Moderna cancer vaccine cuts recurrence risk 42% but the stock sinks. $MRNA fell about 17% even though its melanoma vaccine with Merck’s Keytruda lowered the risk of the cancer coming back or death by 42%. The data leaked early and the stock had already run up big, so traders sold the news. @petenajarian @jonnajarian read the results because #ITSNOTANOPTION 📙 Rebel Investors Club daily market briefings 3 months free 👉 https://t.co/4AOUpzO3my
在 X 查看 ↗